CA3186586A1 - Compound embodiments for treating retinal degeneration and method embodiments of making and using the same - Google Patents

Compound embodiments for treating retinal degeneration and method embodiments of making and using the same

Info

Publication number
CA3186586A1
CA3186586A1 CA3186586A CA3186586A CA3186586A1 CA 3186586 A1 CA3186586 A1 CA 3186586A1 CA 3186586 A CA3186586 A CA 3186586A CA 3186586 A CA3186586 A CA 3186586A CA 3186586 A1 CA3186586 A1 CA 3186586A1
Authority
CA
Canada
Prior art keywords
compound
subject
formula
heteroaliphatic
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3186586A
Other languages
English (en)
French (fr)
Inventor
Wenwei Huang
Anupam Mondal
Wei Zheng
Yu Holly CHEN
Anand Swaroop
Manju SWAROOP
Gregory Tawa
Samantha PAPAL
Zhiji LUO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA3186586A1 publication Critical patent/CA3186586A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3186586A 2020-07-02 2021-07-01 Compound embodiments for treating retinal degeneration and method embodiments of making and using the same Pending CA3186586A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047858P 2020-07-02 2020-07-02
US63/047,858 2020-07-02
PCT/US2021/040157 WO2022006439A2 (en) 2020-07-02 2021-07-01 Compound embodiments for treating retinal degeneration and method embodiments of making and using the same

Publications (1)

Publication Number Publication Date
CA3186586A1 true CA3186586A1 (en) 2022-01-06

Family

ID=77227100

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3186586A Pending CA3186586A1 (en) 2020-07-02 2021-07-01 Compound embodiments for treating retinal degeneration and method embodiments of making and using the same

Country Status (6)

Country Link
US (1) US20230301984A1 (https=)
EP (1) EP4175636A2 (https=)
JP (1) JP2023532134A (https=)
AU (1) AU2021300425A1 (https=)
CA (1) CA3186586A1 (https=)
WO (1) WO2022006439A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4705277A1 (en) * 2023-04-27 2026-03-11 Kiora Pharmaceuticals Pty Ltd Method of treating vision loss in a human subject with photoreactive compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489108B1 (en) * 1989-08-21 1996-03-13 Beth Israel Hospital Association Use of spiperone derivatives for immunosuppression
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
CA2383499C (en) 1999-10-21 2009-11-24 Alcon Universal Ltd. Drug delivery device
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
CN101534826A (zh) * 2006-04-14 2009-09-16 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性（amd）的方法
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009089399A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
US10258613B2 (en) * 2014-02-05 2019-04-16 The Board Of Regents Of The University Of Oklahoma Compositions for treating retinal degeneration and methods of production and use thereof
US11406709B2 (en) * 2014-09-15 2022-08-09 Trustees Of Boston University Therapeutic and research application of PDCL3
US10322087B2 (en) * 2015-03-16 2019-06-18 Mireca Medicines Gmbh Targeted liposomal delivery of cGMP analogues
US20210338770A1 (en) * 2018-10-15 2021-11-04 Osaka University Medicament for improving or preventing symptoms relating to retina and/or light reception and method for screening for substance capable of improving or preventing symptoms relating to retina and/or light reception

Also Published As

Publication number Publication date
US20230301984A1 (en) 2023-09-28
AU2021300425A1 (en) 2023-02-02
WO2022006439A3 (en) 2022-02-10
EP4175636A2 (en) 2023-05-10
WO2022006439A2 (en) 2022-01-06
JP2023532134A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
JP7757036B2 (ja) Ｋｖ７チャネル活性化剤の構成および使用方法
KR102726637B1 (ko) 6-아미노이소퀴놀린의 일가-(산) 염 및 이의 용도
KR20130098154A (ko) 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 신규 화합물
KR102733897B1 (ko) Cftr 조절제 및 이의 사용방법
JP2023512828A (ja) クロマカリムプロドラッグ療法のための改善された方法及び組成物
JP2024144702A (ja) 網膜疾患の治療のための眼内または経口投与用医薬組成物
JP2009196973A (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
JP7664861B2 (ja) 眼障害の治療のための化合物
CA3186586A1 (en) Compound embodiments for treating retinal degeneration and method embodiments of making and using the same
US20130131101A1 (en) Tetrahydropyridoethers for treatment of amd
JP2012006918A (ja) イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤
CN105348302B (zh) 一种噻唑并[3,2‑a]嘧啶酮衍生物及其药物组合物和用途
US8476258B2 (en) Compound having activity of blocking NMDA receptor channel, and pharmaceutical agent using the same
JP7706376B2 (ja) 神経修復方法
US20230089949A1 (en) Small molecules for treating age-related retinal diseases
US10253045B2 (en) Crystalline forms of a therapeutic compound and uses thereof
JP2025531367A (ja) Ｔｒｐｖ１アンタゴニストの結晶多形形態およびその製剤
WO2023100918A1 (ja) 新規ニコチンアミド化合物及びその用途
CA3235692A1 (en) Modified forms of ambroxol for therapeutic use
CN119768168A (zh) 用于治疗眼部疾病用途的三唑
KR20110126132A (ko) 4,6-디클로로-1η-인돌-2-카르복실산 유도체 또는 이의 염을 유효 성분으로서 함유하는 시신경 장애의 예방 또는 치료제

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250408

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250408

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250408

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250409

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250414

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250414

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250417

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250516

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260223